Is It Too Late to Buy Citius Pharmaceuticals Stock?

Is It Too Late to Buy Citius Pharmaceuticals Stock?

Shares of Citius Pharmaceuticals (NASDAQ: CTXR) have shot about 270% higher this year. Citius Pharmaceuticals doesn't have any source of revenue at the moment, but that could change if the FDA approves one of four proprietary products currently under development. The company's lead candidate, Mino-Lok, is an antibiotic lock solution for the treatment of patients with catheter-related blood infections.